Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019

Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in s...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-02, Vol.18 (2), p.e0281555-e0281555
Main Authors: Nduaguba, Sabina O, Tran, Phuong T, Choi, Yoonyoung, Winterstein, Almut G
Format: Article
Language:English
Subjects:
Age
Ambulatory care
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Biology and life sciences
Bronchitis
Child
Child, Preschool
Children
Codes
Confidence intervals
Health risks
Hospitalization
Humans
Immunoprophylaxis
Infant
Infants
Infections
Medicine and Health Sciences
Palivizumab - therapeutic use
Pediatrics
People and Places
Pneumonia
Population statistics
Reinfection
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus, Human
Risk
Risk groups
Seasons
United States - epidemiology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3
cites cdi_FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3
container_end_page e0281555
container_issue 2
container_start_page e0281555
container_title PloS one
container_volume 18
creator Nduaguba, Sabina O
Tran, Phuong T
Choi, Yoonyoung
Winterstein, Almut G
description Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in support of this recommendation is limited. We estimated population-based re-infection rates from 2011-2019 in children
doi_str_mv 10.1371/journal.pone.0281555
format article
fullrecord <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2777358707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3b9b61d1c5c748f58d607d9c206ab356</doaj_id><sourcerecordid>2777358707</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3</originalsourceid><addsrcrecordid>eNptUltrFDEUDqLYuvoPRAO--OCsuUySyUtBipdCQVD7HDJJZjfLbLImmcL8e7PutLTiQ5KTc77znQsfAK8xWmMq8MddnFLQ4_oQg1sj0mHG2BNwjiUlDSeIPn1gn4EXOe8QYrTj_Dk4o1xIxqk8B_6HywefdIlphnkOZi5ej_DWpynD5HwYnCk-hgz1PoYNrA4dSv0FC-c4VY_Z-tEmF2oIlq2DN8EXZ-HPoovLHyBBGDf1ki_Bs0GP2b1a3hW4-fL51-W35vr716vLT9eNYYSXRjLMOaLY2nq4JNoi2WI6aOn6rrda4rYjFEuHqu1wR5HEnaCWmKGlve7pCrw98R7GmNWypayIEIKyTiBREVcnhI16pw7J73WaVdRe_XXEtFE6FW9Gp2gve44tNsyIthtYZzkSVhqCeC1VV7gCF0u1qd87a1woSY-PSB9Hgt-qTbxVUtKWYlQJ3i8EKf6eXC5q77Nx46iDi9Op7xa1mB37fvcP9P_TtSeUSTHn5Ib7ZjBSR-XcZamjctSinJr25uEg90l3UqF_AFbvwSE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2777358707</pqid></control><display><type>article</type><title>Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Nduaguba, Sabina O ; Tran, Phuong T ; Choi, Yoonyoung ; Winterstein, Almut G</creator><contributor>Abidi, Syed Hani</contributor><creatorcontrib>Nduaguba, Sabina O ; Tran, Phuong T ; Choi, Yoonyoung ; Winterstein, Almut G ; Abidi, Syed Hani</creatorcontrib><description>Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in support of this recommendation is limited. We estimated population-based re-infection rates from 2011-2019 in children &lt;5 years since RSV risk remains relatively high in this age group. Using claims data from private insurance enrollees, we established cohorts of children &lt;5 years who were followed to ascertain annual (July 1-June 30) and seasonal (November 1- February 28/29) RSV recurrence estimates. Unique RSV episodes included inpatient encounters with RSV diagnosis ≥30 days apart, and outpatient encounters ≥30 days apart from each other as well as from inpatient encounters. The risk of annual and seasonal re-infection was calculated as the proportion of children with a subsequent RSV episode in the same RSV year/season. Over the 8 assessed seasons/years (N = 6,705,979) and across all age groups annual inpatient and outpatient infection rates were 0.14% and 1.29%, respectively. Among children with a first infection, annual inpatient and outpatient re-infection rates were 0.25% (95% confidence interval (CI) = 0.22-0.28) and 3.44% (95% CI = 3.33-3.56), respectively. Both infection and re-infection rates declined with age. While medically-attended re-infections contributed numerically only a fraction of the total RSV infections, re-infections among those with previous infection in the same season were of similar magnitude as the general infection risk, suggesting that a previous infection may not attenuate the risk for a re-infection.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0281555</identifier><identifier>PMID: 36795639</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Age ; Ambulatory care ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antiviral Agents - therapeutic use ; Biology and life sciences ; Bronchitis ; Child ; Child, Preschool ; Children ; Codes ; Confidence intervals ; Health risks ; Hospitalization ; Humans ; Immunoprophylaxis ; Infant ; Infants ; Infections ; Medicine and Health Sciences ; Palivizumab - therapeutic use ; Pediatrics ; People and Places ; Pneumonia ; Population statistics ; Reinfection ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - prevention &amp; control ; Respiratory Syncytial Virus, Human ; Risk ; Risk groups ; Seasons ; United States - epidemiology ; Viruses</subject><ispartof>PloS one, 2023-02, Vol.18 (2), p.e0281555-e0281555</ispartof><rights>Copyright: © 2023 Nduaguba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>2023 Nduaguba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Nduaguba et al 2023 Nduaguba et al</rights><rights>2023 Nduaguba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3</citedby><cites>FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3</cites><orcidid>0000-0002-6518-5961 ; 0000-0001-6383-2603</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2777358707/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2777358707?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36795639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Abidi, Syed Hani</contributor><creatorcontrib>Nduaguba, Sabina O</creatorcontrib><creatorcontrib>Tran, Phuong T</creatorcontrib><creatorcontrib>Choi, Yoonyoung</creatorcontrib><creatorcontrib>Winterstein, Almut G</creatorcontrib><title>Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in support of this recommendation is limited. We estimated population-based re-infection rates from 2011-2019 in children &lt;5 years since RSV risk remains relatively high in this age group. Using claims data from private insurance enrollees, we established cohorts of children &lt;5 years who were followed to ascertain annual (July 1-June 30) and seasonal (November 1- February 28/29) RSV recurrence estimates. Unique RSV episodes included inpatient encounters with RSV diagnosis ≥30 days apart, and outpatient encounters ≥30 days apart from each other as well as from inpatient encounters. The risk of annual and seasonal re-infection was calculated as the proportion of children with a subsequent RSV episode in the same RSV year/season. Over the 8 assessed seasons/years (N = 6,705,979) and across all age groups annual inpatient and outpatient infection rates were 0.14% and 1.29%, respectively. Among children with a first infection, annual inpatient and outpatient re-infection rates were 0.25% (95% confidence interval (CI) = 0.22-0.28) and 3.44% (95% CI = 3.33-3.56), respectively. Both infection and re-infection rates declined with age. While medically-attended re-infections contributed numerically only a fraction of the total RSV infections, re-infections among those with previous infection in the same season were of similar magnitude as the general infection risk, suggesting that a previous infection may not attenuate the risk for a re-infection.</description><subject>Age</subject><subject>Ambulatory care</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biology and life sciences</subject><subject>Bronchitis</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Codes</subject><subject>Confidence intervals</subject><subject>Health risks</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunoprophylaxis</subject><subject>Infant</subject><subject>Infants</subject><subject>Infections</subject><subject>Medicine and Health Sciences</subject><subject>Palivizumab - therapeutic use</subject><subject>Pediatrics</subject><subject>People and Places</subject><subject>Pneumonia</subject><subject>Population statistics</subject><subject>Reinfection</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - prevention &amp; control</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>Risk</subject><subject>Risk groups</subject><subject>Seasons</subject><subject>United States - epidemiology</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUltrFDEUDqLYuvoPRAO--OCsuUySyUtBipdCQVD7HDJJZjfLbLImmcL8e7PutLTiQ5KTc77znQsfAK8xWmMq8MddnFLQ4_oQg1sj0mHG2BNwjiUlDSeIPn1gn4EXOe8QYrTj_Dk4o1xIxqk8B_6HywefdIlphnkOZi5ej_DWpynD5HwYnCk-hgz1PoYNrA4dSv0FC-c4VY_Z-tEmF2oIlq2DN8EXZ-HPoovLHyBBGDf1ki_Bs0GP2b1a3hW4-fL51-W35vr716vLT9eNYYSXRjLMOaLY2nq4JNoi2WI6aOn6rrda4rYjFEuHqu1wR5HEnaCWmKGlve7pCrw98R7GmNWypayIEIKyTiBREVcnhI16pw7J73WaVdRe_XXEtFE6FW9Gp2gve44tNsyIthtYZzkSVhqCeC1VV7gCF0u1qd87a1woSY-PSB9Hgt-qTbxVUtKWYlQJ3i8EKf6eXC5q77Nx46iDi9Op7xa1mB37fvcP9P_TtSeUSTHn5Ib7ZjBSR-XcZamjctSinJr25uEg90l3UqF_AFbvwSE</recordid><startdate>20230216</startdate><enddate>20230216</enddate><creator>Nduaguba, Sabina O</creator><creator>Tran, Phuong T</creator><creator>Choi, Yoonyoung</creator><creator>Winterstein, Almut G</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6518-5961</orcidid><orcidid>https://orcid.org/0000-0001-6383-2603</orcidid></search><sort><creationdate>20230216</creationdate><title>Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019</title><author>Nduaguba, Sabina O ; Tran, Phuong T ; Choi, Yoonyoung ; Winterstein, Almut G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Ambulatory care</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biology and life sciences</topic><topic>Bronchitis</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Codes</topic><topic>Confidence intervals</topic><topic>Health risks</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunoprophylaxis</topic><topic>Infant</topic><topic>Infants</topic><topic>Infections</topic><topic>Medicine and Health Sciences</topic><topic>Palivizumab - therapeutic use</topic><topic>Pediatrics</topic><topic>People and Places</topic><topic>Pneumonia</topic><topic>Population statistics</topic><topic>Reinfection</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - prevention &amp; control</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>Risk</topic><topic>Risk groups</topic><topic>Seasons</topic><topic>United States - epidemiology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nduaguba, Sabina O</creatorcontrib><creatorcontrib>Tran, Phuong T</creatorcontrib><creatorcontrib>Choi, Yoonyoung</creatorcontrib><creatorcontrib>Winterstein, Almut G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nduaguba, Sabina O</au><au>Tran, Phuong T</au><au>Choi, Yoonyoung</au><au>Winterstein, Almut G</au><au>Abidi, Syed Hani</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-02-16</date><risdate>2023</risdate><volume>18</volume><issue>2</issue><spage>e0281555</spage><epage>e0281555</epage><pages>e0281555-e0281555</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in support of this recommendation is limited. We estimated population-based re-infection rates from 2011-2019 in children &lt;5 years since RSV risk remains relatively high in this age group. Using claims data from private insurance enrollees, we established cohorts of children &lt;5 years who were followed to ascertain annual (July 1-June 30) and seasonal (November 1- February 28/29) RSV recurrence estimates. Unique RSV episodes included inpatient encounters with RSV diagnosis ≥30 days apart, and outpatient encounters ≥30 days apart from each other as well as from inpatient encounters. The risk of annual and seasonal re-infection was calculated as the proportion of children with a subsequent RSV episode in the same RSV year/season. Over the 8 assessed seasons/years (N = 6,705,979) and across all age groups annual inpatient and outpatient infection rates were 0.14% and 1.29%, respectively. Among children with a first infection, annual inpatient and outpatient re-infection rates were 0.25% (95% confidence interval (CI) = 0.22-0.28) and 3.44% (95% CI = 3.33-3.56), respectively. Both infection and re-infection rates declined with age. While medically-attended re-infections contributed numerically only a fraction of the total RSV infections, re-infections among those with previous infection in the same season were of similar magnitude as the general infection risk, suggesting that a previous infection may not attenuate the risk for a re-infection.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>36795639</pmid><doi>10.1371/journal.pone.0281555</doi><orcidid>https://orcid.org/0000-0002-6518-5961</orcidid><orcidid>https://orcid.org/0000-0001-6383-2603</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2023-02, Vol.18 (2), p.e0281555-e0281555
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2777358707
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Age
Ambulatory care
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Biology and life sciences
Bronchitis
Child
Child, Preschool
Children
Codes
Confidence intervals
Health risks
Hospitalization
Humans
Immunoprophylaxis
Infant
Infants
Infections
Medicine and Health Sciences
Palivizumab - therapeutic use
Pediatrics
People and Places
Pneumonia
Population statistics
Reinfection
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus, Human
Risk
Risk groups
Seasons
United States - epidemiology
Viruses
title Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A18%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Respiratory%20syncytial%20virus%20reinfections%20among%20infants%20and%20young%20children%20in%20the%20United%20States,%202011-2019&rft.jtitle=PloS%20one&rft.au=Nduaguba,%20Sabina%20O&rft.date=2023-02-16&rft.volume=18&rft.issue=2&rft.spage=e0281555&rft.epage=e0281555&rft.pages=e0281555-e0281555&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0281555&rft_dat=%3Cproquest_plos_%3E2777358707%3C/proquest_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c526t-95166031dd31d692ad09413fa9eb8bda91482319e0da9e183091873d2cf43bab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2777358707&rft_id=info:pmid/36795639&rfr_iscdi=true